Signal
Slate’s $245M PIPE Could Fund Unproven Migraine Drug
Raleigh-based Slate Medicines has a conditional path to Nasdaq and substantial private financing, while its lead migraine candidate remains in early clinical development.
Tag
Slate Medicines
Recent Triangle Technology Signals posts filed under Slate Medicines.
